Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease.

ABSTRACT:

Background

Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular events.

Objectives

This study evaluated the association between high-sensitivity cardiac troponin I concentration and cardiovascular events in patients with COPD and heightened cardiovascular risk.

Methods

In a double-blind randomized controlled trial, 16,485 patients with COPD and cardiovascular disease or risk factors were randomized to once daily inhaled placebo, fluticasone furoate (100 μg), vilanterol (25 μg), or their combination. Plasma high-sensitivity cardiac troponin I concentrations were measured in a subgroup of 1,599 patients. Outcomes were on-treatment cardiovascular events and COPD exacerbations over a median of 18 months, and cardiovascular death

SUBMITTER: Adamson PD 

PROVIDER: S-EPMC6119211 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature